Gregory St John

1.1k total citations
28 papers, 825 citations indexed

About

Gregory St John is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Gregory St John has authored 28 papers receiving a total of 825 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 9 papers in Hematology and 6 papers in Genetics. Recurrent topics in Gregory St John's work include Rheumatoid Arthritis Research and Therapies (19 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Systemic Lupus Erythematosus Research (7 papers). Gregory St John is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Systemic Lupus Erythematosus Research (7 papers). Gregory St John collaborates with scholars based in United States, Germany and Spain. Gregory St John's co-authors include Carl Nathan, Nathan Brot, Herbert Weissbach, Jia Ruan, W. Todd Lowther, Brian W. Matthews, Toshinori Hoshi, Stefan H. Heinemann, Hediye Erdjument‐Bromage and Paul Tempst and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecular Microbiology and Infection and Immunity.

In The Last Decade

Gregory St John

27 papers receiving 810 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory St John United States 12 379 187 115 103 101 28 825
Miranda Wilson United Kingdom 19 652 1.7× 56 0.3× 83 0.7× 83 0.8× 25 0.2× 26 1.2k
June Ereño‐Orbea Spain 15 494 1.3× 150 0.8× 106 0.9× 56 0.5× 124 1.2× 31 866
Peter W. Melera United States 23 1.2k 3.2× 92 0.5× 156 1.4× 96 0.9× 49 0.5× 64 1.9k
Tao-Hsin Chang Taiwan 14 835 2.2× 156 0.8× 82 0.7× 349 3.4× 43 0.4× 29 1.5k
Gregory Tombline United States 23 956 2.5× 29 0.2× 155 1.3× 94 0.9× 36 0.4× 41 1.6k
Hyun Sik Jun South Korea 20 310 0.8× 502 2.7× 21 0.2× 69 0.7× 69 0.7× 48 1.2k
Trayambak Basak India 19 527 1.4× 80 0.4× 49 0.4× 56 0.5× 16 0.2× 48 1.0k
Heike Lange France 23 1.8k 4.7× 112 0.6× 38 0.3× 91 0.9× 91 0.9× 32 2.5k
Hironobu Eguchi Japan 17 539 1.4× 49 0.3× 18 0.2× 49 0.5× 40 0.4× 39 1.0k
Christian Fédérici France 16 235 0.6× 43 0.2× 40 0.3× 48 0.5× 20 0.2× 23 724

Countries citing papers authored by Gregory St John

Since Specialization
Citations

This map shows the geographic impact of Gregory St John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory St John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory St John more than expected).

Fields of papers citing papers by Gregory St John

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory St John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory St John. The network helps show where Gregory St John may publish in the future.

Co-authorship network of co-authors of Gregory St John

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory St John. A scholar is included among the top collaborators of Gregory St John based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory St John. Gregory St John is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Curtis, Jeffrey R., Michael E. Weinblatt, Kenneth G. Saag, et al.. (2020). Data‐Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry. Arthritis Care & Research. 73(4). 471–480. 13 indexed citations
3.
4.
Genovese, Mark C., Gerd R Burmester, Laure Gossec, et al.. (2020). THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS. Annals of the Rheumatic Diseases. 79. 299–299.
5.
Genovese, Mark C., Gerd R Burmester, Owen Hagino, et al.. (2020). Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research & Therapy. 22(1). 206–206. 26 indexed citations
6.
Kovalenko, Pavel, Anne Paccaly, Anita Boyapati, et al.. (2020). Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. CPT Pharmacometrics & Systems Pharmacology. 9(7). 405–414. 9 indexed citations
7.
Xu, Christine, Ashique Rafique, Terra Potocky, et al.. (2020). Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters. The Journal of Clinical Pharmacology. 61(5). 714–724. 32 indexed citations
8.
Genovese, Mark C., Désirée van der Heijde, Yong Lin, et al.. (2019). Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 5(2). e000887–e000887. 29 indexed citations
9.
Curtis, Jeffrey R., Michael E. Weinblatt, Kenneth G. Saag, et al.. (2019). OP0122 EXPLORING HETEROGENEITY IN RHEUMATOID ARTHRITIS: PATIENT PROFILING THROUGH PRINCIPAL COMPONENT AND CLUSTER ANALYSIS OF THE BRASS REGISTRY. Annals of the Rheumatic Diseases. 78. 135–136. 1 indexed citations
10.
11.
Burmester, Gerd R, Vibeke Strand, Andrea Rubbert‐Roth, et al.. (2019). Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open. 5(2). e001017–e001017. 9 indexed citations
12.
Curtis, Jeffrey R., Yong Lin, Karthinathan Thangavelu, et al.. (2019). FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 702–703. 1 indexed citations
13.
Fleischmann, Roy, Mark C. Genovese, Yong Lin, et al.. (2019). Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up. Lara D. Veeken. 59(2). 292–302. 55 indexed citations
14.
15.
Xu, Christine, Qiang Lü, Anne Paccaly, et al.. (2019). FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA). Annals of the Rheumatic Diseases. 78. 719–720. 4 indexed citations
16.
Burmester, Gerd R, Howard Amital, Andrea Rubbert‐Roth, et al.. (2019). SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE). Annals of the Rheumatic Diseases. 78. 1138–1139. 2 indexed citations
17.
John, Gregory St, et al.. (2009). A 2.4GHz non-contact biosensor system for continuous vital-signs monitoring. 1–3. 9 indexed citations
18.
Lee, Warren L., Benjamin D. Gold, Crystal M. Darby, et al.. (2008). Mycobacterium tuberculosis expresses methionine sulphoxide reductases A and B that protect from killing by nitrite and hypochlorite. Molecular Microbiology. 71(3). 583–593. 63 indexed citations
19.
Weissbach, Herbert, Toshinori Hoshi, Stefan H. Heinemann, et al.. (2002). Peptide Methionine Sulfoxide Reductase: Structure, Mechanism of Action, and Biological Function. Archives of Biochemistry and Biophysics. 397(2). 172–178. 268 indexed citations
20.
John, Gregory St, Nathan Brot, Jia Ruan, et al.. (2001). Peptide methionine sulfoxide reductase fromEscherichia coliandMycobacterium tuberculosisprotects bacteria against oxidative damage from reactive nitrogen intermediates. Proceedings of the National Academy of Sciences. 98(17). 9901–9906. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miranda Wilson Breakdown of academic impact, for papers by June Ereño‐Orbea Breakdown of academic impact, for papers by Peter W. Melera Breakdown of academic impact, for papers by Tao-Hsin Chang Breakdown of academic impact, for papers by Gregory Tombline Breakdown of academic impact, for papers by Hyun Sik Jun Breakdown of academic impact, for papers by Trayambak Basak Breakdown of academic impact, for papers by Heike Lange Breakdown of academic impact, for papers by Hironobu Eguchi Breakdown of academic impact, for papers by Christian Fédérici
Rankless by CCL
2026